SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
SCTO Platforms - scto
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK - ScienceDirect
Home | SAKK
ZOOM SAKK 30/10 HOVON 103 Indication ... - Cancer Lausanne
Indication Lymphome agressif à cellules B récidivant ou ... - CHUV
BIG Members | Breast International Group
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group. - ppt download
International Journal of Colorectal Disease | Volume 32, issue 1
CAREFOR, The Clinical Academic Cancer Research Forum
GitHub - IDSC-io/sakk: Swiss Group for Clinical Cancer Research SAKK
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Tweets with replies by SAKK (@SAKK_ch) / Twitter
SAKK | BIG against breast cancer
Swiss Group for Clinical Cancer Research (SAKK) – Life Science Zurich Business Network
Talidox | InnoMedica
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized. - ppt download
Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). - Abstract - Europe PMC
Swiss Medical Weekly - Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer
SAKK Swiss Group for Clinical Cancer Research | LinkedIn
Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07) - Montemurro - 2018 - Cancer - Wiley Online Library
SAKK Swiss Group for Clinical Cancer Research | LinkedIn
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
Home | SAKK
SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
